V600E mutation detected in a case of Rosai-Dorfman disease

about

V600E mutation detected in a case of Rosai-Dorfman disease

Item

http://www.wikidata.org/entity/Q57723954

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

V600E mutation detected in a case of Rosai-Dorfman disease

@en

V600E mutation detected in a case of Rosai-Dorfman disease

@nl

type

Item

label

V600E mutation detected in a case of Rosai-Dorfman disease

@en

V600E mutation detected in a case of Rosai-Dorfman disease

@nl

prefLabel

V600E mutation detected in a case of Rosai-Dorfman disease

@en

V600E mutation detected in a case of Rosai-Dorfman disease

@nl

P1476

V600E mutation detected in a case of Rosai-Dorfman disease

@en

P2093

Aliana Meneses Ferreira

http://www.w3.org/2001/XMLSchema#string

André Néder Ramires Abdo

http://www.w3.org/2001/XMLSchema#string

Frédéric Charlotte

http://www.w3.org/2001/XMLSchema#string

Giancarlo Fatobene

http://www.w3.org/2001/XMLSchema#string

Jean-François Emile

http://www.w3.org/2001/XMLSchema#string

Vanderson Rocha

http://www.w3.org/2001/XMLSchema#string

Zofia Hélias-Rodzwicz

http://www.w3.org/2001/XMLSchema#string

P2860

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.

How I treat Langerhans cell histiocytosis.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.

Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

P304

e377-e379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2018.190934

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Valerie Taly

Julien Haroche

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29748446

http://www.w3.org/2001/XMLSchema#string

P921

hematology

P932

6068029

http://www.w3.org/2001/XMLSchema#string